Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553211 | 1.00 | MEN1 (0.58) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL2789282 | 1.00 | MEN1 (0.58) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL16041071 | 0.95 | HPGD (0.55) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1901176 | 0.91 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL17761666 | 0.91 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL22991886 | 0.91 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| Ammonia Solution, Strong SCHEMBL28699367 | 0.89 | HPGD (0.50) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL7885177 | 0.88 | HPGD (0.48) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL7885175 | 0.88 | HPGD (0.48) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL7853341 | 0.86 | MEN1 (0.56) | MEN1ALDH1A1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4587424-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | Bridgene Biosciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025111408-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY AND HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20050215582-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005044797-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005007083-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | HTR7, HTR2C, HTR1A | MEN1 4149/4885ALDH1A1 1138/4885MAPT 4269/4885 |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | MEN1 911/4885ALDH1A1 393/4885MAPT 4418/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | MEN1 1977/4885ALDH1A1 3306/4885MAPT 2421/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | MEN1 3807/4885ALDH1A1 3594/4885MAPT 4745/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | MEN1 3559/4885ALDH1A1 1320/4885MAPT 2740/4885 |
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | CCR4, CCR1, CCR3 | MEN1 2660/4885ALDH1A1 1894/4885MAPT 2314/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | MEN1 2738/4885ALDH1A1 3523/4885MAPT 3335/4885 |
| US-20050215582-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | MEN1 4068/4885ALDH1A1 1591/4885MAPT 3515/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | MEN1 3169/4885ALDH1A1 3008/4885MAPT 3989/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | MEN1 911/4885ALDH1A1 393/4885MAPT 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.